A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats.

Off-label oclacitinib is effective and well-tolerated in cats with dermatological disease.

This retrospective case series evaluated oclacitinib administration in 238 cats with dermatological disease, analyzing clinical efficacy, adverse events, and optimal dosing regimens. The mean initial dosage was 1.89 mg/kg/day, with monotherapy successfully controlling clinical signs in 59% of cats. Twice-daily dosing (mean 1.85 mg/kg/day) controlled signs in 59% of responders, while once-daily dosing (mean 1.05 mg/kg/day) was effective in 41%. Primary diagnoses managed included feline atopic skin syndrome (61%) and pemphigus foliaceus (29%), with median treatment duration of 271.5 days. Adverse events occurred in 13.4% of cats, with neutropaenia being most common (6.3%), followed by gastrointestinal signs (4%) and lethargy (1.7%). Other rare adverse events included infection, hyperactivity, elevated liver enzymes, and elevated creatinine. Overall, adverse events were mild and responsive to dose reduction. The safety and efficacy profile appeared comparable to oclacitinib use in dogs, supporting off-label feline use as a viable treatment option for immune-mediated skin conditions.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.